Description

CagriTirz (Cagrilintide + Tirz) Research Blend – Lyophilized

Product Specification of CagriTirz

• Active Components : Cagrilintide + Tirz
• CAS Registry Nos. : 1415456-99-3 (Cagri) & 2023788-19-2 (Tirz)
• Target Mechanism : Tetra-Agonist (Amylin, Calcitonin, GLP-1, GIP)
• Physical Form : Single Vial (Pre-Mixed Co-Lyophilized Cake)
• Purity Grade : ≥99% (HPLC Verified Precision Blend)
• Reconstitution Vehicle : Bacteriostatic Water (Add slowly, Do not shake)
• Stability (Liquid) : Unstable (Use Immediately / Ex Tempore Only)
• Storage (Powder) : Stable at -20°C (Keep Desiccated)
• Molecular Weights : ~4,409 g/mol (Cagri) / ~4,813 g/mol (Tirz)

Disclaimer : For Research Use Only (RUO). Not for human use.

Product Format : Lyophilized Powder

Grade : Certified Reference Material (≥99% HPLC)

Classification : Tetra-Agonist Research Target

CagriTirz represents the frontier of polypharmacological research in 2026. This experimental combination investigates the synergistic effect of “stacking” a dual-incretin agonist (Tirz) with a long-acting amylin analogue (Cagri).

Current literature (ADA 84th Scientific Sessions, Abstract 300-OR) suggests this combination utilizes a “Pincer Movement” on energy homeostasis :

1. Hypothalamus : Tirz engages the arcuate nucleus to reduce hunger signals.
2. Hindbrain : Cagri targets the Area Postrema (which lacks a BBB) to brake gastric emptying and induce satiety physically.

Warning : This is a high-complexity research target. Mixing these peptides in a single solution without buffering correction can lead to immediate precipitation due to conflicts at their isoelectric points (pI).

 

Chemical Identity & Mechanism

 

1 – The “Tetra-Agonist” Hypothesis : The CagriTirz research model is designed to test efficacy ceilings. While Tirz monotherapy achieves ~22.5% weight reduction (SURMOUNT-1 data), the addition of Cagri theoretically targets the 26–30% range.

 

2 – Off-Label “Grey Market” Risks : Netnography of unregulated usage often cites significant adverse outcomes due to unknown impurities. Profound Aminos supplies reagents strictly as Certified Reference Materials (CRM) for analytical chemistry and instrument calibration (HPLC/MS). Our products are engineered to help laboratories identify contaminants and establish chemical purity baselines, strictly prohibiting biological administration or personal use.

 

3 – The Clinical Benchmark (NCT06221969 Context) : Current industry focus is defined by the “Head-to-Head” efficacy trials. Specifically, Clinical Trial NCT06221969 is currently investigating CagriSema (Cagrilintide + Semaglutide) directly against Tirz to determine glycemic superiority.

 

The Research Gap: While large pharma is pitting these molecules against each other, independent research models are pivoting to investigate the additive potential of combining the winner of the GIP/GLP-1 class (Tirz) with the amylin potency of Cagri. This “Tetra-Stack” represents the theoretical apex of current metabolic pharmacotherapy.

 

Chemical Structures

 

2D Chemical Structure of Cagrilintide (CAS 1415456-99-3)

Long-acting Amylin analogue peptide for metabolic research. Research Grade HPLC purity verification.

Cagrilintide Molecular Structure. A 29-amino acid Amylin analogue modified with a C20 fatty acid. Note the specific amino acid substitutions designed for high-affinity binding to Amylin (AMY) and Calcitonin (CTR) receptors. Storage: Acidic pH required.

Chemical Structure of Tirz (CAS 2023788-19-2)

Dual GIP/GLP-1 receptor agonist peptide. Laboratory reference material for mass spectrometry calibration.

A 39-amino acid linear peptide engineered for dual GIP/GLP-1 agonism. The structure highlights the C20 fatty diacid moiety attached via a hydrophilic linker, critical for albumin binding and half-life extension in research models. Storage: Neutral pH required.

 

Comparative Research Context

 

Direct Comparison: The “Triple G” vs. “Tetra” Stack

 

Feature	CagriTirz (Tetra-Stack)	Reta (Triple G)	Sema (Mono)
Molecule Type	Dual Peptide Combination	Single Molecule	Single Molecule
Targets	GLP-1 / GIP / Amylin / Calcitonin	GLP-1 / GIP / Glucagon	GLP-1
Primary Mechanism	Intake Reduction (Satiety + Gastric Braking)	Metabolic Burn (Thermogenesis)	Appetite Suppression
Est. Efficacy	Potential >25% (Synergistic)	~24–26% (Phase 2)	~15–17%
Research Utility	“Stall Breaking,” High-Tolerance Models	Metabolic Rate Research	Baseline Control
Complexity	High (Requires pH Management)	Moderate	Low

 

Why Researchers source from PROFOUND AMINOS

 

In the “Grey Market,” chemical incompatibility is often ignored. We operate on physicochemical facts.

 

1 – Precision Co-Lyophilization (Green)

 

Manual mixing introduces error. We utilize Co-Lyophilization Technology to lock Cagri and Tirz in a stable crystalline matrix. This ensures the exact ratio is preserved in powder form without degradation.

 

Our Standard :

 

We supply a Precision Co-Lyophilized Blend, where Cagrilintide and Tirz are locked in a stable crystalline matrix to prevent the formation of immunogenic amyloid aggregates until the moment of reconstitution.

 

USA Cold-Chain Logistics (Growth)

 

Both Amylin analogues and GIP-based peptides are highly sensitive to thermal degradation.

 

2 – The “Fresh-Reconstitution” Protocol (Growth)

 

Blends of Cagri (Acidic) and Tirz (Neutral) are chemically sensitive once wet.

 

• The Risk : Pre-mixed liquid pens sold by others degrade in transit.
• Our Protocol : We supply strictly Lyophilized Powder.

 

The chemical stability remains intact in the frozen state. The researcher activates the solution strictly at the moment of analysis, ensuring maximum potency and zero hydrolysis.

 

“Triple G” Compliance :

 

• We adhere to strict Federal compliance.
• We do not use full brand names (e.g., Zep* or Mou*) to respect trademarks.
• We make no medical claims. All data is derived from peer-reviewed sources like Nature Medicine and NEJM.

 

Handling & Stability

 

Storage : Store lyophilized vials at -20^. Keep desiccated.

 

Reconstitution :

 

• Cagrilintide : Reconstitute with bacteriostatic water adjusted to acidic pH if storing long-term, or use immediately.
• Tirz : Reconstitute with standard neutral bacteriostatic water.

 

HANDLING WARNING : This blend is for Ex Tempore use only. Do not store the solution after mixing, as cloudiness (precipitation) will occur due to pH conflict.

 

REGULATORY & COMPLIANCE STATEMENT

 

Classification : Research Use Only (RUO). Not for human consumption, cosmetic, diagnostic, or clinical use.

 

FDA Warning : These products are FDA Category 2 research chemicals. They are not approved for the treatment of any disease (obesity, diabetes) in humans. The FDA and other regulatory bodies have issued specific alerts regarding the compounding of peptides; Profound Aminos is not a compounding pharmacy. We sell bulk lyophilized powder strictly for laboratory analysis (GC/MS, HPLC) and non-clinical research.

 

Safety Protocol : Cagri and Tirz are potent metabolic agents. In research models, accidental exposure or ingestion can cause severe hypoglycemia and gastrointestinal distress.

 

• Handling : Wear nitrile gloves and protective eyewear.
• Disposal : Biohazard sharps compliant.
• SDS : Refer to the Safety Data Sheet for CAS 1415456-99-3 and CAS 2023788-19-2 before handling.

 

Frequently Asked Questions

 

Q1:Why is this supplied as a powder instead of a liquid?

 

A: Chemical stability. Mixing Cagri (Acidic) and Tirz (Neutral) in liquid causes precipitation. Our Co-Lyophilized Powder remains stable until the moment of use.

 

Q2: How does the “Tetra-Agonist” mechanism differ from Retatrutide?

 

A: Structure. Reta is a single molecule targeting GLP-1, GIP, and Glucagon (Triple G). CagriTirz is a dual-peptide stack targeting GLP-1, GIP, Amylin, and Calcitonin. While Reta drives metabolic rate via Glucagon, the CagriTirz stack utilizes the Amylin pathway to physically “brake” gastric emptying at the hindbrain level, offering a completely different mechanism for satiety research.

 

Q3: What data support the efficacy of this combination?

 

A: Preclinical data presented at the ADA 84th Scientific Sessions (Abstract 300-OR) indicated that a combination of low-dose Cagri and low-dose Tirz in rodent models achieved -11.0% weight loss, significantly outperforming high-dose monotherapy of either agent. This suggests a synergistic ceiling effect that has not yet been fully mapped in human trials.

 

Q4: Can I use standard Bacteriostatic Water for both?

 

A: Technically, yes, but optimal solubility for Cagri is achieved with a slightly acidic vehicle. However, for most short-term experimental workflows, standard USP Bacteriostatic Water…”